FDA requests minor labeling changes for NRx Pharmaceuticals' preservative — free ketamine

NRx Pharmaceuticals received an FDA review letter requesting minor labeling changes for its preservative-free ketamine product. The FDA requested sample labeling using the proposed proprietary name, still under review, ahead of the November 10, 2026, review deadline. Final manufacturing process validation runs are underway to meet product launch requirements. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. NRX Pharmaceuticals Inc. published the original content used to generate this news brief via (Ref. ID: 202610150827PRIMZONEFULLFEED9846515) on October 15, 2026, and is solely responsible for the information contained therein. (C)